Aq­tu­al rais­es $31M to guide rheuma­toid arthri­tis treat­ments

The di­ag­nos­tics com­pa­ny Aq­tu­al has raised $31 mil­lion to help de­vel­op its test that’s de­signed to pre­dict how pa­tients re­spond to rheuma­toid arthri­tis drugs. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.